ATR kinase inhibitor AZD6738 potentiates CD8+ T cell–dependent antitumor activity following radiation

Journal: Journal of Clinical Investigation

Published: 2018-06-28

DOI: 10.1172/jci96519

Affiliations: 12

Authors: 16

Go to article
Institutions FC
Department of Radiation Oncology, Pitt, United States of America (USA) 0.34
Department of Pharmaceutical Sciences, Pitt, United States of America (USA) 0.13
Department of Microbiology and Molecular Genetics, Pitt, United States of America (USA) 0.09
Department of Immunology, Pitt, United States of America (USA) 0.06
Inova Schar Cancer Institute, Inova Health System, United States of America (USA) 0.06
AstraZeneca IMED Biotech Unit Cambridge, United Kingdom (UK) 0.06
Department of Radiation Oncology and Molecular Radiation Sciences, JHU, United States of America (USA) 0.05
Department of Oncology: The Sidney Kimmel Comprehensive Cancer Center, JHU, United States of America (USA) 0.05
James Buchanan Brady Urological Institute, JHU, United States of America (USA) 0.05
Graduate Program in Cellular and Molecular Medicine (CMM), JHU, United States of America (USA) 0.05
Department of Otolaryngology, Pitt, United States of America (USA) 0.03
Department of Pharmacology and Chemical Biology, Pitt, United States of America (USA) 0.03

Return